P athological cardiac remodeling is the process by which a compensatory response is transformed to a maladaptive response on reacting to mechanical load (eg, valvular regurgitation or stenosis) or humoral factors (eg, catecholamine) and is the strongest predictor of heart failure, arrhythmia, and sudden death. In the early stage of this pathological process, to enhance cardiac pump function, the heart undergoes hypertrophic growth via the enlargement of individual myocytes without effects on cardiac function. However, continued insult would ultimately leads to cardiac chamber enlargement and fibrosis with perturbed contractile performance. In addition to histological and functional deterioration, cardiac remodeling is a composite of cellular and molecular changes, including protein synthesis, sarcomeric organization, fibrosis, cell death, and energy metabolism. Although the pathogenesis and development of pathological hypertrophy have been studied extensively, the complete molecular network has not been sufficiently dissected. Moreover, we have recently demonstrated that a number of protein molecules traditionally regarded as immunologic molecules exert key regulatory effects on this process. [1][2][3] Given the prominent and omnipresent role of the immune network in cell biology, the identification of new immune regulators in cardiac hypertrophy will provide additional insights into the mechanism and treatment of this life-threatening disease.
P athological cardiac remodeling is the process by which a compensatory response is transformed to a maladaptive response on reacting to mechanical load (eg, valvular regurgitation or stenosis) or humoral factors (eg, catecholamine) and is the strongest predictor of heart failure, arrhythmia, and sudden death. In the early stage of this pathological process, to enhance cardiac pump function, the heart undergoes hypertrophic growth via the enlargement of individual myocytes without effects on cardiac function. However, continued insult would ultimately leads to cardiac chamber enlargement and fibrosis with perturbed contractile performance. In addition to histological and functional deterioration, cardiac remodeling is a composite of cellular and molecular changes, including protein synthesis, sarcomeric organization, fibrosis, cell death, and energy metabolism. Although the pathogenesis and development of pathological hypertrophy have been studied extensively, the complete molecular network has not been sufficiently dissected. Moreover, we have recently demonstrated that a number of protein molecules traditionally regarded as immunologic molecules exert key regulatory effects on this process. [1] [2] [3] Given the prominent and omnipresent role of the immune network in cell biology, the identification of new immune regulators in cardiac hypertrophy will provide additional insights into the mechanism and treatment of this life-threatening disease.
Since its discovery, adaptor protein Src homology 2-B3 (SH2B3) has been highlighted as a nonredundant negative modulator in hematopoietic and B-cell development. [4] [5] [6] Adaptor proteins, which function as molecular scaffolds to orchestrate cellular signals, possess multiple functions, including organization and control of protein translocation, mediation of protein-protein interactions, and recruitment of required enzyme substrates. Based on structural similarities, SH2B3 (also referred to as Lnk) belongs to the SH2B family
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of adaptor proteins, which also contains SH2B1 and SH2B2 (APS). Full-length SH2B comprises 5 structurally important domains: the carboxyl-terminal SH2 domain, which is responsible for binding to the phosphotyrosine residue; the pleckstrin homology domain, which is essential for the recognition of phosphoinositides and the translocation of SH2B3 to the cell membrane; a dimerization domain, which mediates homodimerization and heterodimerization between members of the SH2B family; a proline-rich region and a conserved C-terminal CBL recognition motif. 7 SH2B3 functions as an adaptor molecule downstream of various tyrosine kinases and lacks enzymatic activity. SH2B3 also exerts pleiotropic effects on cardiovascular diseases independent of its immune activities. [8] [9] [10] Recent genome-wide association studies have indicated that variants of SH2B3 single-nucleotide mutations are associated with increased susceptibility to hypertension, 11 myocardial infarction, 12 and vascular disease, including retinal vessels 13 and peripheral arteries. 14 However, the regulatory effects and potential mechanisms of action of SH2B3 in these diseases are largely unknown. These clinical discoveries motivated us to investigate the potential role of SH2B3 in cardiovascular systems.
Herein, we observed a striking increase in SH2B3 expression in human samples of cardiac remodeling. The same phenomenon was observed in a mouse model of pressure overload-induced hypertrophy, which permitted us to investigate the potential role of SH2B3 in cardiac remodeling. The prohypertrophic effect of SH2B3 was first examined in in vitro cell studies. Consistent with the cell investigations, aortic banding (AB)-induced hypertrophy was greatly ameliorated by SH2B3 inactivation in SH2B3 knockout (SH23B3 −/− ) mice. By contrast, gain-of-function experiments in which SH2B3 overexpression was targeted to the hearts exaggerated cardiac remodeling. Thus, we have identified a causal role of SH2B3 in pathological hypertrophy. The responsible downstream signaling cascade of SH2B3 is not to be the mitogen-activated protein kinase (MAPK) pathway, as typically observed for the immune system, but rather the focal adhesion kinase (FAK)-phosphoinositide 3-kinase (PI3K)-AKTmammalian target of rapamycin (mTOR)/glycogen synthase kinase 3β (GSK3β) signaling pathway. In addition, a novel SH2B3 −/− rat strain was successfully generated using a transcription activator-like effector nuclease (TALEN) approach and was applied to further ascertain the requirement of SH2B3 in cardiac remodeling.
Materials and Methods
All animal experiments were conducted in accordance with National Institutes of Health guidelines and were approved by the Animal Care and Use Committees of Renmin Hospital of Wuhan University and Tongji Hospital of Huazhong University of Science and Technology. All experimental procedures involving human samples were approved by the Human Research Ethics Committees of Renmin Hospital of Wuhan University and Tongji Hospital of Huazhong University of Science and Technology, and written informed consent was obtained before heart sample collection. A expanded Methods section is available in the online-only Data Supplement, which includes detailed methods of the following: reagents, human heart samples, mice used in experiments, generation of SH2B3 knockout rats, animal models of pressure overload-induced cardiac remodeling, echocardiography and hemodynamic measurements, histological analysis, primary cardiomyocyte culture, recombinant adenoviral infection and immunofluorescence, quantitative real-time polymerase chain reaction, western blot analysis, and statistical analysis.
Results

Upregulation of SH2B3 Protein Expression in Failing Hearts Suggests a Role in Cardiac Remodeling
The potential role of SH2B3 in cardiac hypertrophy was implicated from failing hearts explanted from patients undergoing heart transplantation. As shown in Figure 1A to 1D, compared with normal donor heart, the abundance of SH2B3 were dramatically elevated in the left ventricles (LVs) of both dilated cardiomyopathy and hypertrophic cardiomyopathy, along with increases in the hypertrophic markers atrial natriuretic peptide and β-myosin heavy chain. The results of the animal experiments were consistent with these findings. At 4 weeks after the C57BL/6 mice underwent AB surgery, the expression of SH2B3 was increased, accompanied by increased expression of hypertrophic markers ( Figure 1E -1G). However, SH2B3 expression levels at 8 weeks after surgery, although still above basal levels, were slightly decreased compared with 4 weeks after surgery ( Figure 1E and 1F). Immunohistochemical staining of SH2B3 on heart tissue sections demonstrated that most of SH2B3 were localized in the cytoplasm of cardiomyocytes ( Figure 1G ). Collectively, these results raise the possibility that SH2B3 influence cardiac remodeling.
SH2B3 Is a Potent Regulator in Angiotensin-IIInduced Cardiomyocyte Hypertrophy In Vitro
To further consolidate our hypothesis, we performed gainand loss-of-function assays on neonatal rat cardiomyocytes, a well-controlled in vitro experimental system. Increasing and decreasing SH2B3 expression levels of neonatal rat cardiomyocytes were approached by adenoviral SH2B3 and adenoviral shSH2B3 transfection, respectively (Figure 2A and 2B). Hypertrophy was subsequently induced in these cells via angiotensin-II stimulation for 48 hours. In the control adenoviral green fluorescent protein-and nonsense adenoviral shRNA-transfected groups, cardiomyocytes exhibited increased individual cell size ( Figure 2C-2E ) and mRNA levels of hypertrophic markers ( Figure 2F and 2G) after stress. However, the hypertrophic response was blocked in adenoviral shSH2B3-treated cells ( Figure 2C , 2D, and 2F). In sharp contrast, increasing SH2B3 expression robustly promoted cardiomyocyte hypertrophy ( Figure 2C , 2E, and 2G). These results indicate that SH2B3 is indispensable for the promotion of cardiomyocyte hypertrophy in vitro.
Loss of SH2B3 Exerts a Strong Protective Effect Against AB-Induced Cardiac Hypertrophy In Vivo
Hemodynamic analysis showed that AB induced significant and comparable blood pressure elevation in SH2B3 +/+ and SH2B3 −/− mice ( Figure S1D ). The increment in heart size was first estimated by echocardiography in live mice. Under isoflurane anesthesia, no difference in heart rates was observed between groups ( Figure S1B ). The LV end-systolic diameter and LV end-diastolic diameter, which reflect heart chamber dimensions in vivo, increased more pronouncedly after 4 weeks of pressure overload in the control mice ( Figure 3A and 3B). Importantly, cardiac contractive function (reflected by the ejection fraction % and fractional shortening %) deterioration was alleviated in SH2B3 −/− mice ( Figure S1C ; Figure 3C ). Consistently, hemodynamic comparison conducted by cardiac catheterization revealed that both systolic function (assessed by ejection fraction % and maximal dP/dt; Figure S1E and S1F) and diastolic function (assessed by minimal dP/dt; Figure S1G ) were largely preserved in SH2B3 −/− mice.
The ameliorated hypertrophic response in SH2B3 −/− mice was further confirmed by morphological examinations. Macroscopically, SH2B3 inactivation greatly alleviated the hypertrophic response, as evidenced by smaller whole-heart transversal sectional area ( Figure 3D, top) . Microscopically, individual cardiomyocyte hypertrophy was blunted after SH2B3 deficiency ( Figure 3D , middle and bottom) as assessed by decrease in the cardiomyocyte cross-sectional area ( Figure 3E ). The hypertrophic phenotype was also supported by tibia length and body weight-corrected heart mass measurement ( Figure 3F and 3G). The ratio of lung weight/body weight, which indicates the development of pulmonary congestion, was also decreased after SH2B3 inactivation ( Figure 3H ). Fibrosis, another characteristic of pathological hypertrophy, was greatly mitigated in SH2B3 −/− mice as displayed by less perivascular and interstitial collagen deposition ( Figure 3I and 3J). It should be noted that the loss of SH2B3 had no effect on nonstressed hearts. 
Cardiac-Specific SH2B3 Overexpression Potentiates the Progression of Pressure Overload-Induced Cardiac Hypertrophy
We then asked whether SH2B3 overexpression may promote cardiomyocyte hypertrophy in vivo. We selectively overexpressed SH2B3 in cardiac myocytes under the control of the α-myosin heavy chain promoter. Four founders were established that exhibited 1.4-to 3.7-fold SH2B3 overexpression relative to the wild-type control ( Figure S2A and S2B). The most robust overexpression founder, which has 3.7-fold SH2B3 expression relative to control, was used for the in vivo gain-of-function experiments. This strain was fertile and exhibited no apparent abnormalities under basal conditions. Concordant with our hypothesis, cardiac-targeted SH2B3 overexpression resulted in a disastrous hypertrophic response to pressure overload for 4 weeks. The exacerbated LV dilation was first identified by echocardiographic examinations, which exhibited increased LV end-diastolic diameter and LV endsystolic diameter under similar heart rates (Figure 4A and 4B; Figure S2C ). Both echocardiographic and hemodynamic analyses indicated that the enlarged heart chambers were accompanied by more severe impairments of cardiac function in SH2B3 transgenic mice ( Figure 4C ; Figure S2D -S2F). However, there was an increase in dP/dT (maximum) and dP/ dT (minimum) ( Figure S2G and S2H). These results were caused by increased end-diastolic volume and end-systolic volume ( Figure S2I and S2J). 15 In agreement with the functional conclusions, the morphological examinations revealed that both the whole-heart enlargement and individual myocyte hypertrophy were more pronounced in SH2B3 transgenic mice ( Figure 4D and 4E). Similarly, SH2B3 overexpression dramatically increased both heart and lung weight after pressure overload ( Figure 4F-4H) . Compared with the picrosirius red staining slices of the control mice, the LVs of the Collectively, these in vivo experiments indicate that SH2B3 overexpression rendered the heart more susceptible to maladaptive cardiac hypertrophy.
Alternations in the FAK-PI3K-AKT-mTOR/GSK3β Signaling Pathway Underlie the SH2B3-Mediated Hypertrophic Response In Vivo and In Vitro
Copious evidence have proved that the MAPK signaling pathways play a fundamental role in the development of pathological cardiac hypertrophy. 16 Moreover, extracellular signal-regulated kinase 1/2 (ERK1/2) signaling is also regulated by SH2B3 in hematopoietic cells. 5, [17] [18] [19] Thus, we tested whether the regulatory effect on ERK1/2 signaling might underlie the mechanism of SH2B3 in promoting cardiac hypertrophy. In agreement with previous studies, ERK1/2 phosphorylation was substantially increased in hypertrophic hearts ( Figure S3A and S3B) . However, the activation of neither ERK1/2 nor the upstream MAPK kinase 1/2 was affected by SH2B3 expression levels in different mouse strains ( Figure  S3A and S3B). We also compared the other 2 branches of the MAPK superfamily, namely, the c-Jun N-terminal kinase and p38, which have also been implicated in SH2B3-regulated cell biology. 18, 20 As displayed in Figure S3A and S3B, although both pathways were activated in hypertrophy, we did not observe perceptible difference among the SH2B3 −/− mice, the SH2B3 transgenic mice, and their controls. Our findings unexpectedly demonstrated that the involvement of SH2B3 in cardiac remodeling was independent of the MAPK pathway, which suggests that additional mechanisms may be responsible for SH2B3-regulated pathological hypertrophic responses.
We and others have previously demonstrated that AKT is a potent effector molecule downstream of multiple stimuli to induce hypertrophy. 21, 22 In this study, western blot analysis revealed that SH2B3 ablation abrogated AB-induced AKT phosphorylation ( Figure 5A and 5B). Conversely, SH2B3 overexpression greatly enhanced AKT activation ( Figure 5C-5D) . Accordingly, the phosphorylation of downstream mTOR and GSK3β was altered in accordance with the changes occurred on AKT ( Figure 5A-5D ). Taken together, these results indicate that AKT is responsible for the SH2B3-mediated hypertrophic response.
To gain broader insight into SH2B3 and AKT signaling, we tracked several classic activators upstream of AKT. Persad et al 23 demonstrated that the serine kinase integrin-linked kinase (ILK) could directly phosphorylate AKT on serine 343. However, ILK was similarly activated in all mouse strains after pressure overload ( Figure 6A-6D ). PI3K, a protein kinase and lipid enzyme, has long be recognized as another AKT upstream signal. Indeed, the phosphorylation of the key p85 subunit in PI3K was decreased in SH2B3 knockout hearts and, conversely, increased in SH2B3-overexpressing hearts ( Figure 6A-6D) . However, it remains to be decided the specific kinase that catalyzes the activation of PI3K, because SH2B3 have no enzymatic activities. Among the known candidates that may directly activate PI3K, the FAK was recently identified as a prohypertrophic signal transducer. 24 In fact, the activation state of FAK was greatly influenced by SH2B3 expression levels. As shown in Figure 6A and 6B, FAK phosphorylation is reduced in SH2B3 −/− heart tissues after stress. By contrast, SH2B3 overexpression leads to increased pressure overload-induced FAK activation ( Figure 6C and 6D) .
These observations suggest that SH2B3 may act through FAK to exert its effect. To further substantiate these findings, we confirmed the in vivo results in ex vivo cardiomyocytes. Neonatal rat cardiomyocytes were infected with the indicated adenovirus as described above to artificially set the SH2B3 expression levels. After stressed with angiotensin-II for 60 minutes, FAK phosphorylation was robustly elevated in control adenoviral shRNA-and adenoviral green fluorescent proteininfected cells (Figure 6E-6H) . Consistent with the in vivo studies, SH2B3 reduction by adenoviral shSH2B3 greatly abrogated angiotensin-II-induced FAK activation ( Figure 6E and 6F) . By contrast, SH2B3 gain-of-function promoted angiotensin-IIinduced FAK activation ( Figure 6G and 6H) . Moreover, activation of downstream AKT, mTOR, and GSK3β varied depending on altered SH2B3 expression and FAK activation ( Figure 6E-6H ). In conclusion, the FAK-PI3K-AKT-mTOR/GSK3β axis is a key target of SH2B3 in defining prohypertrophic activity.
Cardiac Hypertrophy Is Blunted in SH2B3 Knockout Rats After Pressure Overload
Nearly the same hypertrophic phenotype occurred in the rat cardiomyocytes, which prompted us to investigate whether the regulatory effects of SH2B3 were generic across species.
Indeed, in wild-type Sprague-Dawley rats challenged with abdominal AB surgery, SH2B3 expression was increased in LVs ( Figure 7A and 7B), consistent with observations in humans and mice. We subsequently generated SH2B3 knockout rats using the TALEN technique as noted in the methods. A TALEN pair was designed to target SH2B3 exon1 as outlined in Figure S4A . Then, the in vitro transcribed TALEN SH2B3 mRNAs were injected into fertilized rat oocytes to splice SH2B3. Three founders of 8 live births with cleavage products were chosen and sequenced to verify the precise mutation of the indels (Figure S4B and S4C) . Afterward, founder numbers 4 to 8 were selected for sibling mating into homozygosity. The presence of mutant and wild-type alleles was verified by polymerase chain reaction analysis as illustrated in Figure S4D . The absence of intact protein in the presence of the SH2B3 null allele was ascertained by western blot ( Figure S4E ). The homozygous SH2B3 −/− rats were viable, fertile, normal in size, and exhibited no phenotypic abnormalities.
These rats were subsequently stressed with pressure overload by AB surgery for 4 weeks. As illustrated in Figures 7C-7E and S4G, echocardiographic examinations revealed that SH2B3 inactivation ameliorated heart chamber dilation accompanied by preserved cardiac function in live rats. The heart and lung mass increments were all reduced in SH2B3 −/− rats ( Figure 7F-7H) . Morphologically, pressure overloadtriggered cardiomyocyte enlargement, and, perivascular and interstitial fibrosis were all attenuated by SH2B3 deficiency (Figure 7I-7K) . At the molecule level, SH2B3 deficiency Figure 7L and 7M) , which also occurred in mice and ex vivo cells. Collectively, SH2B3 knockout in rats attenuated cardiac hypertrophy via a mechanism similar to that in mice.
Discussion
SH2B3 was initially cloned from a rat lymph node cDNA library and recognized as an essential transducer in T-cell receptor signaling. 25 Since its discovery, the highest recognition of SH2B3 is its functional significance in immune cells and hematopoietic homeostasis. SH2B3 is essential for normal peripheral B-cell expansion 6 and bone marrow progenitor cell accumulation of both erythroid 19 and macrophage colony-stimulating factor. 27 SH2B3 also promotes self-renewal in hematopoietic progenitor cells. 20, 26 However, the role of SH2B3 in nonhematopoietic systems, particularly heart biology, remains poorly investigated. The implication of SH2B3 in hypertrophic biology was inspired by human samples. Although minimally expressed under basal conditions, SH2B3 expression is strikingly elevated in human failing hearts and mouse and rat hypertrophic hearts. Gain-and loss-of-function assays in neonatal rat cardiomyocytes suggested a causal role of SH2B3 in promoting myocyte hypertrophy. Consistent with the cell culture studies, animal studies demonstrated that SH2B3 inactivation blunted cardiac hypertrophy, whereas forced SH2B3 expression predisposed the heart vulnerable to hypertrophy. The altered hypertrophic response was not solely demonstrated by heart size but also supported by fibrosis and cardiac function analysis. It should be noted that under basal conditions, neither SH2B3 knockout nor SH2B3 overexpression affected cardiac structure and function. Thus, using genetic approaches, we identified SH2B3 as a novel regulator in the process of pressure overload-induced hypertrophy and as a stress sensor only under stressed conditions will SH2B3 take effect.
In an effort to better understand the molecular mechanisms by which SH2B3 functions, we first examined the MAPK signaling pathway. Various prohypertrophic stimuli function via the activation of ERKs, c-Jun N-terminal kinases, and p38, which trigger numerous intracellular targets and, in turn, launch the hypertrophy process. In terms of ERK1/2, studies performed in different systems have yielded contradictory conclusions: SH2B3 is a negative modulator of the ERK1/2 signaling pathway downstream of c-kit, 5, 18 EpoR, 19 c-Mpl, 28, 29 and FLT3 17 on engagement with their specific ligands. Whereas in macrophages, SH2B3 deficiency diminishes ERK1/2 activation when stimulated with M-CSF. Moreover, there are evidences that p38 18, 20, 30 and c-Jun N-terminal kinase 18 are also involved in the signaling downstream of SH2B3. Nonetheless, we obtained no evidence for differences in all 3 branches of MAPK activation among SH2B3 −/− mice, transgenic mice, and wild-type mice. This inconformity might be explained by the fact that SH2B3 plays specific roles via binding to diverse partners to activate or suppress downstream signaling pathways in cell type-or stimulation-specific manners.
We then demonstrated that the altered hypertrophic phenotype affected by SH2B3 expression is attributable to AKT signaling. Acting at the intersection of multiple influent and efferent signals, AKT influences nearly every aspect of cardiac biology. AKT is a serine/threonine protein kinase; following activation, it phosphorylates GSK3β and mTOR and, in turn, initiates the hypertrophic process. AKT phosphorylation at Thr308 generates its active form. However, phosphorylation of Ser473 is required for its full activation. The ILK molecule is an essential hub that propagates hypertrophic signaling at the cytoplasmic tails of integrins. 31 As the name implies, initial studies indicated that ILK possesses serine/ threonine kinase activity and directly phosphorylates AKT at Ser473 to complete its full activation. 32 Moreover, ILK also possesses kinase activity to phosphorylate GSK3β and inhibit its activity. 33 A recent report by Devallière et al 8 demonstrated that ILK is a molecular partner of SH2B3 in the regulation of AKT and GSK3β phosphorylation; thus, it is our first choice to select ILK as a candidate partner in SH2B3-mediated hypertrophic response. However, in our study, despite the increased phosphorylation of AKT and GSK3β in transgenic mice after hypertrophy, ILK phosphorylation was unaltered and vice versa in SH2B3 KO mice. This finding concordant with the results of studies demonstrating that phosphorylation of AKT and GSK3β is separable from increased ILK levels in the failing hearts. 34 This is also supported by recent comments suggesting that ILK might function as an adaptor rather than a kinase in integrin signaling. 35 In addition to ILK, AKT could also be directly activated by phosphoinositide-dependent kinase, which is the downstream effector of PI3K. FAK is a nonreceptor tyrosine kinase and plays a major role in the mediation of signaling initiated from integrins and growth and hormonal factors. When phosphorylated, FAK directly binds to and phosphorylates the p85 subunit of PI3K. 36, 37 Emerging data have revealed a critical role of FAK in the cardiac hypertrophic response. However, ) rats (n=9-10 rats per group). I, At 4 weeks after AB surgery, the hearts were subjected to histological examinations. First panel, hematoxylin and eosin (H&E) staining; second panel, wheat germ agglutinin (WGA) staining; third panel, picrosirius red (PSR) staining for perivascular fibrosis; and fourth panel, PSR staining for interstitial fibrosis (scale bar, 20 μm). J, Statistical results for the individual cardiomyocyte cross-sectional area (n=4 rats and at least 400 cells per group). K, Quantification of the collagen analysis by PSR staining (n=4 rats and at least 60 high-power fields were counted per group). L and M, Activation state and total volume of focal adhesion kinase (FAK), AKT, the mammalian target of rapamycin (mTOR), and glycogen synthase kinase 3β (GSK3β) in the indicated groups 4 weeks after surgery were verified by western blot (n=6 samples for statistical results These results are consistent with our conclusions.
Although FAK is a major mediator of integrin signaling, we did not obtain evidence that SH2B3 regulates the FAK in the integrin cascade. However, previous studies have suggested a role for SH2B3 as an important regulator in integrin signaling. Takizawa et al 39 demonstrated that SH2B3 was important for the regulation of VCAM-1-initiated integrin signaling in hematopoietic stem cells. In platelets, SH2B3 is an essential contributor to the out-in signaling of integrin αIIbβ3.
9 Specifically in endothelial cells, SH2B3 promotes the phosphorylation of FAK and paxillin in the integrin signaling, which subsequently impairs FA disassembly and decreases endothelial migration. 8 Based on these findings, we postulate that SH2B3 may function in integrin signaling to regulate cardiomyocyte hypertrophy.
Rat models have many apparent advantages over mouse models in biomedical research: first, the relatively larger size of rats increases the accuracy of surgical procedures, more measurements can be carried out, and the results are more reliable; second, the rat is more physiologically resemble humans, including more-developed brains and lower heart rates, making it a superior animal for use in neurological and cardiovascular disease research. 40 However, because of the rapid differentiation of rat embryonic stem cells during long-term in vitro culture, 41 the mouse gene targeting technology can be hardly applied to rats in past decades. As a result of the advances in TALEN technology, using genetically modified rats as disease models are achievable. In our study, SH2B3-deficient rats were less vulnerable to pressure overload-induced hypertrophy, consistent with the phenotypes and mechanisms established in mouse studies. These results suggest that the role of SH2B3 in the regulation of cardiac hypertrophy was conserved across species.
In conclusion, the research findings presented here illustrate a key role of SH2B3 in the regulation of cardiac hypertrophic response. Both gain-and loss-of-function experiments demonstrated that SH2B3 regulates the hypertrophic response via the FAK-PI3K-AKT-mTOR/GSK3β signaling cascade.
Perspectives
A better understanding of the molecular network that underlies cardiac hypertrophic growth will provide new possibilities for the clinical management of heart failure. Although SH2B3 has long been recognized as a prototypical immunologic molecule, studies on the role of SH2B3 in cardiovascular diseases are now emerging. The unanticipated role of SH2B3 in hypertrophy identified here will provide further knowledge of the regulation of nonimmune cell activities by immunologic molecules. Our results suggest that SH2B3 will be a promising therapeutic target in drug investigations for the treatment of heart failure progression.
What Is New?
• Src homology 2-B3 (SH2B3) is upregulated in human, mouse, and rat hearts after cardiac remodeling.
• SH2B3 promotes pressure overload-induced cardiac remodeling.
• SH2B3 regulates the cardiac hypertrophic response via the FAK-PI3K-AKT-mTOR/GSK3β pathway.
• A SH2B3 knockout rat line was generated, and the conserved regulatory effect of SH2B3 across species was validated.
What Is Relevant?
• Knowledge of how immune network regulates cardiac remodeling has been limited. Heart rates (B) and ejection fraction (C) were measured by echocardiographic analysis at 4 weeks after aortic banding (AB) surgery (HR: heart rates; bpm: beats per minute; EF: ejection fraction. n=6 or 7 mice per group). D-G, End-systolic pressure (D), EF % (E), dP/dt max (F) and dP/dt min (G) were evaluated by invasive hemodynamic examinations at 4 weeks after AB (dP/dt max indicates the maximum rate of pressure increase; dP/dt min indicates the minimum rate of pressure increase; n=4-7 mice per group). *P<0.05 versus the SH2B3 +/+ sham group; #P<0.05 versus the SH2B3 +/+ AB (4W) group. were measured by echocardiographic analysis at 4 weeks after aortic banding (AB) surgery (HR: heart rates; bpm: beats per minute; EF: ejection fraction. n=6 or 7 mice per group). E-J, Heart functional parameters were determined by hemodynamic examination 4 weeks after AB (EF: ejection fraction; dP/dt max : maximum rate of pressure increase; dP/dt min : minimum rate of pressure increase; n=4-6 mice per group). *P<0.05 versus the SH2B3 NTG sham group; #P<0.05 versus the SH2B3 NTG AB (4W) group. 
